Expression of Pu.1, C/Ebp? and Bach1 Transcription Factors in Immune Cells in Patients with Cancer

Gulnur K. Zakiryanova1*, Elena Kustova2, Nataliya T. Urazalieva2, Emile T. Baimukhametov3, Valeriy A. Makarov4, Galina V. Shurin6, Narymzhan N. Nakisbekov5, Michael R. Shurin6* 1Al-Farabi Kazakh National University, Almaty, Kazakhstan 2Laboratory of Immunology, Scientific Center of Pediatric and Children Surgery, Almaty, Kazakhstan 3Kazakh Medical University of Continuing Education, Department of Oncology, Almaty, Kazakhstan 4Almaty Oncology Center, Department of Oncosurgery, Almaty, Kazakhstan 5Joint Use Center, Atchabarov Scientific Research Institute of Fundamental and Applied Medicine, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan 6Departments of Pathology and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

[1]  M. Shurin,et al.  Cancer-associated Molecular Abnormalities in Human NK cells , 2021, Journal of Cellular Signaling.

[2]  S. Bhide,et al.  On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy , 2021, Journal for ImmunoTherapy of Cancer.

[3]  M. Nakao,et al.  LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα. , 2021, Blood advances.

[4]  Z. Biyasheva,et al.  Notch signaling defects in NK cells in patients with cancer , 2020, Cancer Immunology, Immunotherapy.

[5]  S. Malarkannan,et al.  Transcriptional Regulation of Natural Killer Cell Development and Functions , 2020, Cancers.

[6]  Bin Zhang,et al.  T Cell Dysfunction and Exhaustion in Cancer , 2020, Frontiers in Cell and Developmental Biology.

[7]  J. Kos,et al.  Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis , 2019, Molecular therapy oncolytics.

[8]  K. Igarashi,et al.  To be red or white: lineage commitment and maintenance of the hematopoietic system by the “inner myeloid” , 2019, Haematologica.

[9]  Philipp S. Hoppe,et al.  Inflammatory signals directly instruct PU.1 in HSCs via TNF. , 2019, Blood.

[10]  H. Hosokawa,et al.  Mechanisms of Action of Hematopoietic Transcription Factor PU.1 in Initiation of T-Cell Development , 2019, Front. Immunol..

[11]  Huy Q. Dinh,et al.  Monocyte heterogeneity and functions in cancer , 2019, Journal of leukocyte biology.

[12]  M. Shurin,et al.  Abnormal Expression of c-Myc Oncogene in NK Cells in Patients with Cancer , 2019, International journal of molecular sciences.

[13]  M. Cazzola,et al.  Infection perturbs Bach2- and Bach1-dependent erythroid lineage ‘choice’ to cause anemia , 2018, Nature Immunology.

[14]  Huy Q. Dinh,et al.  Identification of an Early Unipotent Neutrophil Progenitor with Pro-tumoral Activity in Mouse and Human Bone Marrow. , 2018, Cell reports.

[15]  M. Shurin,et al.  Oncogenes in immune cells as potential therapeutic targets , 2018, ImmunoTargets and therapy.

[16]  M. Shurin,et al.  Alterations of oncogenes expression in NK cells in patients with cancer , 2017, Immunity, inflammation and disease.

[17]  P. Coffer,et al.  A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood , 2017, Oncogene.

[18]  T. Kurosaki,et al.  BACH transcription factors in innate and adaptive immunity , 2017, Nature Reviews Immunology.

[19]  A. Hoffmann,et al.  Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells , 2017, Proceedings of the National Academy of Sciences.

[20]  K. Nakayama,et al.  A Bach2-Cebp Gene Regulatory Network for the Commitment of Multipotent Hematopoietic Progenitors. , 2017, Cell reports.

[21]  Mitsuyo Matsumoto,et al.  Transcription Factor Bach1 and Bach2 Operate Erythro-Myeloid Competitive Differentiation By Responding to Environmental Changes , 2016 .

[22]  K. E. Visser,et al.  Neutrophils in cancer: neutral no more , 2016, Nature Reviews Cancer.

[23]  Q. Lu,et al.  The Bach Family of Transcription Factors: A Comprehensive Review , 2016, Clinical Reviews in Allergy & Immunology.

[24]  Marie S. Hasemann,et al.  The multifaceted functions of C/EBPα in normal and malignant haematopoiesis , 2016, Leukemia.

[25]  Mitsuyo Matsumoto,et al.  Transcription Factor Bach1 and Bach2 Control Common Myeloid Progenitor Cell Differentiation Under Infectious Stimuli , 2015 .

[26]  D. Margolis,et al.  Measurements of CD34+/CD45-dim Stem Cells Predict Healing of Diabetic Neuropathic Wounds , 2015, Diabetes.

[27]  Denis Thieffry,et al.  C/EBPα Activates Pre-existing and De Novo Macrophage Enhancers during Induced Pre-B Cell Transdifferentiation and Myelopoiesis , 2015, Stem cell reports.

[28]  E. Passegué,et al.  Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils , 2015, Proceedings of the National Academy of Sciences.

[29]  T. Kurosaki,et al.  The transcription repressors Bach2 and Bach1 promote B cell development by repressing the myeloid program , 2014, Nature Immunology.

[30]  S. Thom,et al.  CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen - changes with oxygen dosage. , 2014, Stem cell research.

[31]  Marie S. Hasemann,et al.  C/EBPα Is Required for Long-Term Self-Renewal and Lineage Priming of Hematopoietic Stem Cells and for the Maintenance of Epigenetic Configurations in Multipotent Progenitors , 2014, PLoS genetics.

[32]  M. Ebina,et al.  Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function , 2013, The Journal of experimental medicine.

[33]  S. Clarke,et al.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.

[34]  Takashi Saito,et al.  Bach2 maintains T cells in a naive state by suppressing effector memory-related genes , 2013, Proceedings of the National Academy of Sciences.

[35]  S. Nutt,et al.  M-CSF instructs myeloid lineage fate in single haematopoietic stem cells , 2013, Nature.

[36]  Bach2 represses effector programmes to stabilize Treg-mediated immune homeostasis , 2013, Nature.

[37]  M. Feuerer,et al.  Monocytes and Macrophages in Cancer: Development and Functions , 2013, Cancer Microenvironment.

[38]  R. DeKoter,et al.  The Transcription Factor PU.1 is a Critical Regulator of Cellular Communication in the Immune System , 2011, Archivum Immunologiae et Therapiae Experimentalis.

[39]  J. Haanstra,et al.  Lineage-instructive function of C/EBPα in multipotent hematopoietic cells and early thymic progenitors. , 2010, Blood.

[40]  S. Weiss,et al.  Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. , 2010, The Journal of clinical investigation.

[41]  Daniel G Tenen,et al.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  V. Buccheri,et al.  CD34-positive cells and their subpopulations characterized by flow cytometry analyses on the bone marrow of healthy allogenic donors. , 2009, Sao Paulo medical journal = Revista paulista de medicina.

[43]  A. Friedman.  Transcriptional control of granulocyte and monocyte development , 2007, Oncogene.

[44]  Mark Ptashne,et al.  On the use of the word ‘epigenetic’ , 2007, Current Biology.

[45]  T. Graf,et al.  Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/EBP alpha and PU.1 transcription factors. , 2006, Immunity.

[46]  B. Porse,et al.  C/EBPα: A tumour suppressor in multiple tissues? , 2006 .

[47]  M. Caligiuri,et al.  Tumor growth impedes natural-killer-cell maturation in the bone marrow. , 2006, Blood.

[48]  B. Porse,et al.  C/EBPalpha: a tumour suppressor in multiple tissues? , 2006, Biochimica et biophysica acta.

[49]  K. Akashi,et al.  Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. , 2005, Blood.

[50]  Li Wu,et al.  PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis , 2005, The Journal of experimental medicine.

[51]  Lina A. Thoren,et al.  Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic Potential A Revised Road Map for Adult Blood Lineage Commitment , 2005, Cell.

[52]  P. Kastner,et al.  Visualizing PU.1 activity during hematopoiesis. , 2005, Experimental hematology.

[53]  T. Golub,et al.  c-Myc Is a Critical Target for C/EBPα in Granulopoiesis , 2001, Molecular and Cellular Biology.

[54]  O. Lantz,et al.  Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. , 2001, Blood.

[55]  H. Singh,et al.  Regulation of B lymphocyte and macrophage development by graded expression of PU.1. , 2000, Science.

[56]  J. D. Di Santo,et al.  The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. , 2000, Blood.

[57]  K. Itoh,et al.  Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site , 1996, Molecular and cellular biology.

[58]  E. Scott,et al.  Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. , 1994, Science.

[59]  D. Liebermann,et al.  Suppression of c-myc and c-myb is tightly linked to terminal differentiation induced by IL6 or LIF and not growth inhibition in myeloid leukemia cells. , 1991, Oncogene.